Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 2,686 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Donald Bergstrom sold 2,686 shares of Relay Therapeutics stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $8.45, for a total value of $22,696.70. Following the completion of the transaction, the insider owned 420,047 shares in the company, valued at $3,549,397.15. The trade was a 0.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Relay Therapeutics Stock Up 0.8%

Shares of NASDAQ RLAY opened at $7.71 on Friday. Relay Therapeutics, Inc. has a 12 month low of $1.77 and a 12 month high of $9.04. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -4.41 and a beta of 1.55. The business has a fifty day simple moving average of $7.96 and a 200-day simple moving average of $5.95.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.04). As a group, sell-side analysts expect that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Commodore Capital LP raised its stake in shares of Relay Therapeutics by 27.3% during the 3rd quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock worth $88,740,000 after purchasing an additional 3,650,000 shares in the last quarter. Vanguard Group Inc. increased its holdings in Relay Therapeutics by 3.1% in the fourth quarter. Vanguard Group Inc. now owns 9,691,445 shares of the company’s stock worth $81,990,000 after buying an additional 295,701 shares during the last quarter. Bellevue Group AG raised its position in Relay Therapeutics by 1.4% during the third quarter. Bellevue Group AG now owns 8,345,610 shares of the company’s stock valued at $43,564,000 after acquiring an additional 114,740 shares in the last quarter. Geode Capital Management LLC lifted its stake in Relay Therapeutics by 5.2% in the second quarter. Geode Capital Management LLC now owns 3,229,666 shares of the company’s stock valued at $11,176,000 after acquiring an additional 159,548 shares during the last quarter. Finally, Millennium Management LLC grew its position in Relay Therapeutics by 14.6% in the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock worth $7,710,000 after acquiring an additional 374,491 shares in the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on RLAY. Wells Fargo & Company raised shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $6.00 to $13.00 in a research note on Friday, December 12th. Oppenheimer raised Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price objective for the company in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

Relay Therapeutics News Summary

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Shares are trading up intraday, sitting above the 200?day moving average—a technical signal some investors view as constructive. MarketBeat RLAY quote
• Neutral Sentiment: Despite the recent sales, insiders still hold large positions (many hundreds of thousands of shares), which reduces the likelihood of a meaningful shift in strategic control; the disclosures show percentage ownership declines but substantial remaining stakes. (See SEC filings linked below.)
• Negative Sentiment: CFO Thomas Catinazzo sold 1,695 shares at an average $8.45 on Jan. 28 (total ~$14.3k), and had also sold 13,820 shares at ~$7.62 on Jan. 27; these filings show a multi-day reduction in the CFO’s ownership. Catinazzo filings
• Negative Sentiment: Insider Peter Rahmer sold 1,354 shares at $8.45 (Jan. 28) and 11,684 shares at $7.62 (Jan. 27), reducing his stake by several percent—more insider selling that can weigh on sentiment. Rahmer filings
• Negative Sentiment: Insider Donald A. Bergstrom sold 2,686 shares at $8.45 and 18,895 shares at $7.62 across Jan. 27–28, cutting his position by ~4%. Large, clustered insider sales can amplify near?term downward pressure. Bergstrom filings
• Negative Sentiment: Market commentary highlights recent weakness in RLAY (example: a note explaining a ~5.2% drop), which may reflect short?term sentiment, sector dynamics, or news-driven selling; that coverage can push momentum lower even if fundamentals are unchanged. Why RLAY is down 5.18%

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.